9390 Towne Centre Drive
Suite 200
San Diego, CA 92121
United States
858 779 3100
https://poseida.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 330
Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Mr. Mark J. Gergen J.D. | Executive Chairman of the Board | 961.8k | N/D | 1963 |
Dr. Kristin Yarema Ph.D. | President, CEO & Director | 711.99k | N/D | 1971 |
Ms. Johanna M. Mylet CPA | Chief Financial Officer | N/D | N/D | 1988 |
Mr. Loren Wagner | Chief Operations Officer | N/D | N/D | N/D |
Ms. Kristin Martin | Chief People & Administration Officer | N/D | N/D | N/D |
Mr. Alexander Chapman | Senior VP of Investor Relations & Corporate Communications | N/D | N/D | N/D |
Mr. Harry J. Leonhardt Esq., J.D. | General Counsel, Chief Compliance Officer & Corporate Secretary | 630.23k | N/D | 1957 |
Dr. Devon J. Shedlock Ph.D. | Chief Scientific Officer of Cell Therapy | N/D | N/D | N/D |
Ms. Lisa Portale | Senior Vice President of Regulatory Affairs | N/D | N/D | N/D |
Dr. Jeffrey W. Winkelman J.D., Ph.D. | Senior VP & Chief Patent Counsel | N/D | N/D | N/D |
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications. It is also involved in the development of P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, colorectal, lung, ovarian, pancreatic, and renal cancers; P-PSMA-ALLO1, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in preclinical development for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC); and P-PSMA-101, an allogeneic CAR-T product candidate under Phase 1 clinical trial for treating mCRPC. In addition, the company engages in the development of P-FVIII-101, a clinical stage liver-directed gene therapy for the in vivo treatment of hemophilia A; P-OTC-101, a clinical stage liver-directed gene therapy for the in vivo treatment of ornithine transcarbamylase deficiency; and P-PAH-101, a clinical stage liver-directed gene therapy for the in vivo treatment of phenylketonuria. It has a research collaboration and license agreement with F. Hoffmann-La Roche Ltd, and Hoffmann-La Roche Inc. The company was incorporated in 2014 and is headquartered in San Diego, California.
La calificación ISS Governance QuickScore de Poseida Therapeutics, Inc. a partir del 1 de mayo de 2024 es 8. Las puntuaciones principales son Auditoría: 7; Junta: 7; Derechos del accionista: 8; Compensación: 9.